BioSpace News Archive

Veracyte, Inc. (Nasdaq: VCYT) today announced that the company has named Angeline (“Angie”) McCabe as vice president, investor relations and corporate communications, effective immediately

Kala Pharmaceuticals Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced that members of its management team will participate in the following upcoming conferences:

erastem, Inc.. (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the appointment of Robert E. Gagnon, an experienced financial executive, as Chief Financial Officer, effective August 28, 2018.

Synlogic announced today that Aoife Brennan, M.B., B.Ch., Synlogic’s interim president and chief executive officer, and chief medical officer, will present a corporate update at the H. C. Wainwright 20th Annual Global Investment Conference

Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has postponed its investor event to discuss its long-term consumer growth strategies and key operational initiatives, previously planned as a conference call for September 25, 2018.

TSO3 Inc. announced today that it has appointed Mr. Martin J. Madden to the Company’s board of directors.

Morphogenesis, Inc., a Tampa, FL-based immunotherapy company celebrates the launch of its first human clinical study in a strategic collaboration with the Cutaneous Oncology Program at Moffitt Cancer Center.

AOFAS® members travel to Vietnam for 17th consecutive year

Sophiris Bio Inc. today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018 at 10:50 a.m. EDT in New York, NY.

Mirati Therapeutics, Inc. will participate in two panel discussions, at the 2018 Citi Biotech Conference in Boston. Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer will represent Mirati at the event.